Article
Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy.
Annals of hematology - 1 Apr 2017
Hiller Jan K, Schmoor Claudia, Gaidzik Verena I, Schmidt-Salzmann Charlotte, Yalcin Arzu, Abdelkarim Mahmoud, Blagitko-Dorfs Nadja, Döhner Konstanze, Bullinger Lars, Duyster Justus, Lübbert Michael, Hackanson Björn
Abstract excerpt
Treatment with hypomethylating agents such as decitabine, which results in overall response rates of up to 50%, has become standard of care in older patients with acute myeloid leukemia (AML) who are not candidates for intensive chemotherapy. However, there still exists a lack of prognostic and predictive molecular biomarkers that enable selection of patients who are likely to benefit from epigenetic therapy....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.